Soligenix, Inc., a late-stage biopharmaceutical company, has released a corporate presentation detailing their focus on developing and commercializing products for the treatment of rare diseases with unmet medical needs. The company operates in two main segments: Specialized BioTherapeutics, which targets orphan diseases and unmet medical needs in oncology and inflammation, and Public Health Solutions, which develops vaccines and therapeutics for military and civilian applications, including responses to ricin exposure, emerging infectious diseases, and viral diseases like Ebola, Marburg, and COVID-19. Soligenix highlights a robust pipeline with products in various stages of clinical trials, including promising candidates for conditions such as psoriasis and Behçet's disease. The presentation underlines collaborations with biotech firms, academia, and government agencies, along with non-dilutive government funding supporting vaccine development. You can access the full presentation through the link below.